Search for content, post, videos

Alligator receives the SwedenBIO Award

SwedenBIO Award 2016

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life science industry”.

The 10th annual SwedenBIO Award was awarded at a price ceremony in Stockholm, Sweden, on Thursday evening. This year’s winner is Alligator Bioscience, whose pioneering research and great business acumen is a source of inspiration to companies throughout the Swedish life science industry, commented SwedenBIO in a press release.

“A true pioneer, Alligator Bioscience has been quick to identify how new therapeutic concepts can be used to develop unique antibodies with potential to extend life for patients with late-stage cancer. Its advanced research and great business acumen has resulted in a commercial agreement of rare scope with one of the world’s largest pharmaceutical companies. Whilst still in an early development phase with elevated project risk, the commercial potential in this agreement is a source of inspiration for life science companies throughout Sweden.”

A confirmation of Alligator’s success

The nominees for SwedenBIO Award 2016 were Alligator Bioscience AB, Aprea AB, CTC Clinical Trial Consultants AB, Dilafor AB, Moberg Pharma AB and Xbrane Biopharma AB. The winner is selected by SwedenBIO’s Board of Directors: Lars Adlersson, Six Year Plan; Ulrica Slåne, AP3/The Third Swedish National Pension Fund; Sarah Fredriksson, Genovis; Jan Erneberg, GE Healthcare; Yvonne Mårtensson, independent board member and adviser; Per Samuelsson, HealthCap; Eva Sjökvist Saers, APL; Thomas Eldered, Recipharm; Magnus Björsne, AstraZeneca; and Johan Brun, Pfizer.

This is confirmation of Alligator´s success in the field, commented the company. Alligator is a privately held Swedish biotech company with a pipeline of immune-activating antibodies for tumor-directed immunotherapy of cancer. In 2015 Alligator granted Janssen Biotech Inc, one of the Janssen Pharmaceutical companies of Johnson & Johnson, an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. Under the agreement Alligator receives an initial up-front payment and aggregated future milestones up to a potential total of 700 MUSD.

SwedenBIO Award recognizes outstanding achievements in Swedish life science that grow awareness and interest in the industry. Beyond the formal recognition of merit and achievement, the prize winner is awarded two delegate tickets to the Nordic Life Science Days on 14-15 September, 2016.

Photo showing: Jonas Ekstrand, CEO SwedenBIO, Mårten Steen, partner Healthcap, Per Norlén, CEO Alligator Bioscience and Lars Adlersson, Chairman of SwedenBIO at the award ceremony.